Biography

Mita Restinia is a lecturer at the Faculty of Health Sciences, UIN Jakarta, Indonesia, and is currently pursuing her PhD at the Department of Public Health, National Cheng Kung University, Taiwan. Her research focuses on pharmacoepidemiology, causal inference, and real-world evidence. Her current study includes a systematic review and meta-analysis, as well as real-world evidence research analyzing the safety and effectiveness of linezolid and other anti-tuberculosis drugs using large databases such as TriNetX and the Indonesian TB database (SITB). She is also deeply interested in applying advanced causal inference and epidemiologic methods to improve tuberculosis treatment outcomes in clinical and public health settings.

Expertise

TB Diagnostics
Public Health

Key Impacts

Linezolid-associated adverse events and outcomes in the treatment of multidrug/rifampicin-resistant TB: A systematic review and meta-analysis of randomised controlled trials

Linezolid-containing regimens demonstrated acceptable safety and efficacy for the treatment of MDR/RR-TB. Lower doses and shorter durations improved tolerability without compromising treatment outcomes. These findings support current WHO-recommended regimens and highlight the potential of linezolid as a key component of shorter, effective MDR/RR-TB treatment strategies.

Source: Conference 2024